Sacubitril/Valsartan to Treat Heart Failure in a Patient with Relapsing Hairy Cell Leukaemia: Case Report.

IF 2.3 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Clinical Medicine Insights. Cardiology Pub Date : 2021-04-13 eCollection Date: 2021-01-01 DOI:10.1177/11795468211010706

Alessandro Lupi, Sara Ariotti, Doranna De Pace, Irene Ferrari, Stefano Bertuol, Lorenzo Monti, Luigina Guasti, Giovanni Vincenzo Gaudio, Carlo Campana

{"title":"Sacubitril/Valsartan to Treat Heart Failure in a Patient with Relapsing Hairy Cell Leukaemia: Case Report.","authors":"Alessandro Lupi, Sara Ariotti, Doranna De Pace, Irene Ferrari, Stefano Bertuol, Lorenzo Monti, Luigina Guasti, Giovanni Vincenzo Gaudio, Carlo Campana","doi":"10.1177/11795468211010706","DOIUrl":null,"url":null,"abstract":"<p><p>Experience with angiotensin-receptor neprilysin inhibitors (ARNI) in oncologic patients with heart failure (HF) is limited. We report a case of ARNI started as first-choice therapy in a patient with relapsing hairy cell leukaemia (HCL) and HF with depressed left ventricular ejection fraction (LVEF). A middle-aged male, previously treated with rituximab for HCL, was scheduled for cardiologic screening before starting a new antineoplastic therapy for cancer relapse. The patient had symptomatic HF with reduced LVEF and high NT-proBNP levels. In this patient, early ARNI treatment was well tolerated and produced a rapid and durable improvement of symptoms, LVEF and NT-proBNP levels. Consequently, the oncologic team could start an experimental treatment with obinutuzumab, with complete HCL remission. In conclusion, in this patient with HCL and HF, ARNI therapy was safe and effective, contributing to undelayed cancer treatment.</p>","PeriodicalId":10419,"journal":{"name":"Clinical Medicine Insights. Cardiology","volume":"15 ","pages":"11795468211010706"},"PeriodicalIF":2.3000,"publicationDate":"2021-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/11795468211010706","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine Insights. Cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/11795468211010706","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 2

Abstract

Experience with angiotensin-receptor neprilysin inhibitors (ARNI) in oncologic patients with heart failure (HF) is limited. We report a case of ARNI started as first-choice therapy in a patient with relapsing hairy cell leukaemia (HCL) and HF with depressed left ventricular ejection fraction (LVEF). A middle-aged male, previously treated with rituximab for HCL, was scheduled for cardiologic screening before starting a new antineoplastic therapy for cancer relapse. The patient had symptomatic HF with reduced LVEF and high NT-proBNP levels. In this patient, early ARNI treatment was well tolerated and produced a rapid and durable improvement of symptoms, LVEF and NT-proBNP levels. Consequently, the oncologic team could start an experimental treatment with obinutuzumab, with complete HCL remission. In conclusion, in this patient with HCL and HF, ARNI therapy was safe and effective, contributing to undelayed cancer treatment.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Sacubitril/缬沙坦治疗复发性毛细胞白血病心力衰竭1例

血管紧张素受体neprilysin抑制剂(ARNI)在肿瘤心力衰竭(HF)患者中的应用经验有限。我们报告一例ARNI作为首选治疗开始复发的毛细胞白血病(HCL)和HF患者的左室射血分数(LVEF)降低。一名中年男性，先前接受利妥昔单抗治疗HCL，计划在开始新的抗肿瘤治疗癌症复发之前进行心脏病筛查。患者有症状性心衰，LVEF降低，NT-proBNP水平高。在该患者中，早期ARNI治疗耐受性良好，症状、LVEF和NT-proBNP水平迅速持久改善。因此，肿瘤学团队可以开始使用obinutuzumab进行实验性治疗，HCL完全缓解。总之，在该HCL和HF患者中，ARNI治疗是安全有效的，有助于延迟癌症治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊